Citations

Clear

1822 citation(s) found for "King, TA".

Clinical phenotypes, autoimmunity and outcomes in Rosai–Dorfman disease: An international multicentre cohort study
Sen, Mitali , Ruan, Gordon J , Reynolds, Samuel , Ali, Haadi , Morlote, Diana M. , Koster, Matthew J , Abeykoon, Jithma P , Salama, Hind , Ahmed, Asra Z , Go, Ronald S , Goyal, Guarav

Mayo Clinic

British Journal of Haematology | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70939 | PMID 43014348 Get It

Summary Rosai–Dorfman disease (RDD) is a rare histiocytic neoplasm with diverse clinical behaviour and immune abnormalities with unknown clinical significance. We performed a retrospective cohort study of 162 patients with RDD from 2003 to 2025 at five international referral centres. Median age was 48 years and 64.8% were female. Multisystem disease occurred in 87 patients (53.7%), commonly involving skin/subcutaneous tissue (49.4%), lymph nodes (39.5%) and bones (34%). Molecular testing was available for 102 patients; 40 (39.2%) were mitogen‐activated protein kinase/rat sarcoma virus oncogene homolog signaling pathway (MAPK/RAS)‐altered, commonly with kirsten rat sarcoma viral oncogene homolog ( KRAS ) or mitogen‐activated protein kinase 1 ( MAP2K/MEK ) alterations. MAPK/RAS alterations were associated with multisystem disease ( p = 0.0034). Autoimmune disease (AID) was documented in 29 patients (17.9%), usually preceding RDD, and 45/95 patients (47.4%) with available autoantibody status had at least one positive autoantibody. Among 153 patients with response data, objective response occurred in 94 (61.4%). Response distribution differed by disease extent; single‐system disease was associated with more complete responses and less progression than multisystem disease. At a median follow‐up of 2.49 years, eight deaths occurred; 5‐year overall survival was 93.4%. AID and autoantibody positivity were not associated with response or overall survival. These findings support disease extent and molecular status as clinically relevant dimensions of RDD assessment, while autoimmune and serological abnormalities should be interpreted in clinical context.
Time-of-Day of Initial Immune Checkpoint Inhibitor Administration and Its Impact on Outcomes in Metastatic Non–Small Cell Lung Cancer
Schultz, Sydney , Mohr, Riley , Cole, Kristin , Knott, Amanda, Amundson, Briana K., King, Elizabeth B , Hardler, Michael , Chittavong, Vayou, Campian, Jian , Dimou, Anastasios

Mayo Clinic

JCO Oncology Practice | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-26-00491 | PMID 42981555 Get It

Purpose Immune checkpoint inhibitors (ICIs) are integral to first-line treatment of metastatic non–small cell lung cancer (NSCLC). Circadian biology may influence antitumor immunity, raising the hypothesis that time-of-day of ICI administration could affect outcomes. We evaluated the association between initial and cumulative ICI administration time-of-day and clinical outcomes in metastatic NSCLC. Materials and Methods We conducted a retrospective cohort study of 778 patients with metastatic NSCLC treated with first-line ICI-containing therapy across Mayo Clinic sites between January 2021 and March 2024. Patients were stratified by time-of-day of first ICI administration: early (0700-1200) versus late (1201-2400). Primary end points were overall survival (OS) and progression-free survival (PFS); the secondary end point was immune-related toxicity. Multivariable Cox proportional hazards models adjusted for clinically relevant covariates. Exploratory analyses evaluated cumulative infusion time-of-day and alternative administration-time thresholds using spline and cut-point analyses. Results Of 778 patients, 277 received early and 501 received late initial ICI administration. Median OS was 1.33 versus 1.48 versus years and median PFS was 0.65 versus 0.67 years in the late and early groups, respectively. Time-of-day of initial ICI administration was not associated with OS (HR, 1.01 [95% CI, 0.85 to 1.20]) or PFS (HR, 1.03 [95% CI, 0.88 to 1.21]). Findings were unchanged after multivariable adjustment. Immune-related toxicity occurred in 26.9% and 24.2% of patients in the late and early groups, respectively ( P = .40). Cumulative infusion time-of-day was not associated with OS or PFS, and spline analyses identified no significant administration-time threshold associated with outcomes. Conclusion In this large real-world cohort of patients with metastatic NSCLC, neither initial nor cumulative ICI administration time-of-day was associated with survival or immune-related toxicity. Prospective studies incorporating chronotype and circadian biomarkers are warranted to further define the role of chronotherapy in immuno-oncology.
Mobile Fall Risk Screening Using the 4-Stage Balance Test With Vestibular Challenge
Bogle, Jamie M. , Zaleski-King, Ashley

Mayo Clinic

American Journal of Audiology | October 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1044/2026_aja-26-00027 | PMID 42961080 Get It

Purpose: The purpose of this study is to explore the use of mobile device technology to measure postural stability and to assess the preliminary effect of an added dynamic vestibular task in the 4-Stage Balance Test (4SBT) in adults over 65 years. It was hypothesized that adding a dynamic vestibular task would make the 4SBT more sensitive in identifying fall risk. Method: Twenty-eight adults aged 70–100 years completed the 4SBT with and without an added vestibular challenge (i.e., with and without a headshake). Postural sway was measured using a mobile device. Participants also completed the Stay Independent Questionnaire (SIQ) and provided self-reported fall and health history. Differences in sway score were compared between conditions. Correlational analyses assessed the association between fall history, fall risk, and sway scores. Results: The addition of a headshake task significantly increased postural sway across all 4SBT stages. Self-reported fall risk was not predicted by sway score; however, significant correlations were observed between self-reported fall risk and sway in more challenging balance conditions, and these relationships were largely unchanged with the added dynamic vestibular task. Although sway score did not reliably distinguish between individuals who did and did not report a fall, fall history was moderately associated with self-reported fall risk and fear of falling. Conclusions: Significant correlations were observed between SIQ and sway score measured in the more challenging balance conditions. These relationships generally remained stable even with the added dynamic vestibular task, suggesting that the SIQ may reflect real-world balance challenges involving vestibular input. Self-reported fear of falling or perceived fall risk likely captures aspects of imbalance not directly reflected in sway scores. Further research with larger, more diverse samples is warranted to assess added the clinical utility of sway score beyond perceived aspects of imbalance to identify fall risk.
Targeted single-nucleus sequencing of 39,800 neurons reveals extensive low-frequency somatic variants
Bidhan, Vanshika , Wynants, Sarah , Vicente, Cristina T, Küçükali, Fahri , Broeck, Marleen Van den , Rooij, Jeroen GJ van, Mol, Merel O. , Kaat, Laura L Donker, Al-Sarraj, Safa, King, Andrew, Troakes, Claire , Schaeverbeke, Jolien, Thal, Dietmar Rudolf , Vandenberghe, Rik , Vandenbulcke, Mathieu , Nguyen, Aivi T. , Reichard, R. Ross , Kofler, Julia, Lopez, Oscar L, White, Charles L. , Boeve, Bradley F. , Graff-Radford, Neill R, Josephs, Keith A, Petersen, Ronald C, Ghayal, Nikhil B , Murray, Melissa E. , Dickson, Dennis W. , Swieten, John C van, Sleegers, Kristel , Seelaar, Harro , Coster, Wouter De , Rademakers, Rosa , Swings, Toon , Rooij, Jeroen van , Kaat, Laura Donker , Bódi, István , Proukakis, Christos , Schaeverbeke, Jolien , Kofler, Julia , Graff‐Radford, Neill R. , Swieten, John C. van , Mol, Merel O , Proukakis, Christos , Thal, Dietmar Rudolf , Vandenberghe, Rik , Nguyen, Aivi T , Reichard, R Ross , White, Charles L , Boeve, Brad , Murray, Melissa E , Dickson, Dennis W , Seelaar, Harro , De Coster, Wouter , Rademakers, Rosa

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.21.753260 | PMID 42817963 Get It

Abstract Recent evidence implicates somatic mutations in disease-associated genes across multiple neurodegenerative disorders, including the identification of two somatic TARDBP variants as a putative cause of frontotemporal lobar degeneration with TDP-43 pathology type C (FTLD-TDP type C). However, these findings remain anecdotal. We performed single-nucleus amplicon sequencing of 39,800 neurons from the superior temporal gyrus of sporadic FTLD-TDP type C patients (34,738 neurons, 52 individuals) and non-demented controls (5,062 neurons, 26 individuals) using the Mission Bio Tapestri platform and investigated somatic variants in TARDBP and other FTLD-TDP-associated genes in a case-control setting. We uncovered an extensive landscape of ultra-low-frequency (<1%) somatic mutations across all analysed genes, including TARDBP . Rare somatic occurrences of known ALS/FTD-associated germline TARDBP variants, including p.N267S and p.M337V, were identified exclusively in patients. Among all targeted genes, TARDBP had the highest proportion of neurons harbouring a somatic variant, and this mutational burden was lower in individuals who died at an older age. Strikingly, the C-terminal domain of TDP-43, where most ALS/FTD germline pathogenic variants reside, exhibited a lower neuronal mutational burden than its other domains. This suggests that neurons harbouring damaging mutations may undergo progressive loss prior to autopsy, leaving only rare survivors at frequencies too low to detect by bulk or small-scale single-cell approaches. Together, our findings provide an unprecedented resolution into the somatic mutational landscape of post-mitotic neurons in FTLD-TDP type C and reveal a gene-specific layer of neuronal mosaicism that current single-cell WGS studies fail to detect.
Immunodominant Antiviral T-cell Responses Outcompete Antitumor T-cell Responses to Reduce the Efficacy of Oncolytic Viroimmunotherapy
Kendall, Benjamin, Liseth, Olivia , Sangsuwannukul, Thanich , Elliott, Natalie , Chiriboga-Yerovi, Maria P. , Thompson, Jill , Swanson, Jack H. , Rizk, Soha , Melcher, Alan , Irshad, Sheeba , Ellis, Paul , Marcano, Rosa M. Diaz , Tonne, Jason , Vile, Richard G. , Kendall, Benjamin Luke , Liseth, Olivia Y , Elliott, Natalie , Thompson, Jill M , Melcher, Alan A , Diaz Marcano, Rosa M , Tonne, Jason M , Irshad, Sheeba , Yerovi, Maria Chiriboga , Rizk, Soha S.

Mayo Clinic

Cancer Research | September 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF17

10.1158/0008-5472.can-25-5683 | PMID 42766426 Get It

Abstract The paradigm in the field of oncolytic virotherapy proposes that tumor cell killing by an oncolytic virus (OV) culminates in the priming of antitumor CD8+ T cells. However, this ignores the impact a highly immunodominant antiviral response against the OV has on the subdominant antitumor response, particularly with regard to the naturally low affinity of tumor antigens to their cognate T-cell receptors. To investigate this experimentally, we first studied the interaction between the two responses in B16 and MC38 tumor models, both expressing ovalbumin (OVA). Contrary to the accepted paradigm, the inflammatory vesicular stomatitis virus (VSV) failed to expand OVA-specific T cells in vivo unless armed with tumor-associated antigen (TAA). In fact, treatment with the control VSV led to the ablation of antitumor T cells and a shift toward dysfunction as determined by the upregulation of markers, including LAG3 and CD39, correlating with lower rates of survival. Combination with anti–PD-1 immune checkpoint blockade therapy significantly improved survival only when VSV expressed TAA. VSV-expressing altered peptide ligand variants of tumor antigens, which evade mechanisms of central tolerance, expanded near self-antigen–specific T cells with the ability to cross-react with tolerized tumor antigens, thus providing an antitumor effector population capable of proliferating in the presence of a potent antiviral response. Taken together, these findings offer a rational approach to OV design which preserves acute antitumor therapy provided by antiviral innate and T-cell responses while promoting the induction of tumor-specific T cells. Significance: Oncolytic viruses can induce an antiviral T-cell response that occludes an antitumor response, challenging the paradigm in the field and elucidating strategies to optimize the efficacy of oncolytic viroimmunotherapy.
Standard Vs. Low Dose Intra-articular Corticosteroid Knee Injections In Obese Patients With Knee Osteoarthritis
Nihalani, Mayank N. , Bracken, Lacey , Pujalte, George GA, Wight, Jeffrey T., Skov, Renata, Arciniegas, Nicolas, King, Shanterian, Maynard, Jennifer R., Troyer, Wesley , Nadwodny, Jeffrey , Skov, Renata P, King, Shanterian, Maynard, Jennifer R.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 18, 2026 | Volume: 58 | Issue: 10S | Pages: No page available

10.1249/01.mss.0001262492.33953.14 Get It

Association between age at Parkinson's disease onset and divorce: An exploratory analysis from the fox insight cohort
Śmiłowska, Katarzyna , Makos, Orsolya , Cristales, Alay Rangel, Mehanna, Raja , Fleisher, Jori , Alcalay, Roy N. , McConvey, Victor, Zhang, Baorong, Savica, Rodolfo , Alcalay, Roy N , Savica, Rodolfo , Wamelen, Daniel J Van , Mákos, Orsolya , Kumar, Kishore R. , Salari, Mehri , McConvey, Victor

Mayo Clinic

Journal of Parkinson’s Disease | September 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/1877718x261479270 | PMID 42746990 Get It

Background Parkinson's disease (PD) typically presents after age 60; however, approximately 10% of individuals experience early-onset PD (EOPD), with symptoms beginning between ages 21 and 50. Beyond motor and non-motor symptoms, PD can impact personal relationships through stigma, social isolation, and emotional burden. This study aims to examine the influence of PD on relationship outcomes such as divorce or separation. Methods This exploratory study analyzed data from the Fox Insight cohort, an online longitudinal research initiative supported by The Michael J. Fox Foundation. We included 470 individuals with self-reported PD who had complete data on marital status (“married” or “divorced”) and age at PD onset. Participants were categorized as having EOPD (<50 years) or late-onset PD (≥50 years). Chi-square tests assessed the association between PD onset group and marital status. A binary logistic regression model further evaluated gender and onset age as predictors of marital status in a subset of 330 participants. Results A significant association was found between PD onset group and marital status, with a higher divorce rate among the EOPD group (17.5%; 7/40) compared to late-onset PD (6.1%; 26/430) (p = 0.017). Logistic regression revealed no statistically significant predictors, though trends suggested lower odds of divorce in men and those with late-onset PD. Conclusion This exploratory analysis identified a potential association between early PD onset and higher divorce rates; however, with only 7 events in 40 EOPD participants, this finding is inherently unstable and should be regarded as hypothesis-generating only. Confirmation in larger, longitudinal cohorts is required before any conclusions can be drawn.
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome
Chen, Alex , Pulido, José S. , Tonne, Jason , Metko, Muriel , Thompson, Jill , Sangsuwannukul, Thanich , Chiriboga-Yerovi, Maria P. , Marcano, Rosa M. Diaz , Webb, Mason , Huff, Amanda L. , Moore, Madelyn , Schuelke, Matthew , Appleton, Elizabeth , Melcher, Alan , Vile, Richard G. , Thompson, Jill M , Diaz Marcano, Rosa M , Webb, Mason James , Schuelke, Matthew R , Irshad, Sheeba , Appleton, Elizabeth , Melcher, Alan A , Kendall, Benjamin Luke , Vile, Richard G , Metko, Muriel , Yerovi, Maria Chiriboga , Irshad, Sheeba , Kendall, Benjamin L.

Mayo Clinic

Cancer Immunology Research | August 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF20

10.1158/2326-6066.cir-25-1589 | PMID 42644627 Get It

Abstract T-cell immune tolerance is established in part through the activity of the autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTEC) of the thymus. AIRE induces expression of peripheral tissue–specific self-antigens for presentation to naïve T cells to promote activation/deletion of autoreactive T cells. This traditional role of AIRE in mTECs is to prevent autoimmunity. Herein, we demonstrate that tumors mimic the role of AIRE in mTECs to evade immune rejection. We found that AIRE induced a profile of “selfness” at the RNA and protein levels which, when presented on major histocompatibility complexes (MHC), shielded the tumor from inherently self-tolerized T cells. Moreover, we describe an in vivo immunotherapy in which engineered changes in AIRE expression in tumor cells altered their profile of selfness, exposing both AIRE-modified and parental unmodified tumor cells to T-cell attack. Therefore, by resetting the immunologic selfness of cancer cells, this AIRE-mediated immunotherapy (i) converted a highly tolerized T-cell compartment into a tumor-reactive T-cell population; (ii) conferred upon nonimmunogenic tumors de novo sensitivity to immune checkpoint blockade; (iii) removed the need to identify potentially immunogenic tumor-associated antigens as targets for generation of T-cell responses; and (iv) lead to potent T cell–mediated rejection of aggressive, immunologically cold, nonimmunogenic tumors. Patient RNA sequencing data showed that the expression of AIRE predicted response to immune therapies with a strong correlation between AIRE expression and markers of T-cell receptor signaling, suggesting that our studies have therapeutic translational value.
TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging
Benatar, Michael, Lagier‐Tourenne, Clotilde , Gregory, Jenna, Al-Chalabi, Ammar, Boeve, Bradley F., Maragakis, Nicholas J., Wuu, Joanne, Zeier, Zane, Onyike, Chiadi, Lewcock, Joe, Hovinga, Collin, Jafar-nejad, Paymaan, Uspenskaya, Olga, Simmons, Adam, Browne, Susan E., Rohrer, Jonathan, Petrucelli, Leonard, Shapiro, Jacquelyn, Scharper, Deb, Boxer, Adam, Staffaroni, Adam M. , Dacks, Penny, Dave, Kuldip D. , Majo, Martina de, Mitic, Laura, Fradette, Stephanie , Haeberlein, Samantha Budd , Simuni, Tanya, Dunn, Billy, Lee, Edward B., Js, Gregory , Benatar, Michael, Barmada, Sami, Jicha, Gregory A. , Al‐Chalabi, Ammar , Boeve, Bradley F. , Jack, Clifford R. , Seeley, William W. , Maragakis, Nicholas J. , Wuu, Joanne , Zeier, Zane R. , Hovinga, Collin A. , Jafar‐Nejad, Paymaan , Uspenskaya, Olga, Simmons, Adam, Browne, Susan E. , Petrucelli, L, Ostrow, Lyle W. , Dacks, Penny A. , Turner, Martin R. , Majo, Martina de , Simuni, Tanya , McMillan, Corey T. , Lee, Edward B.

Mayo Clinic

JAMA Neurology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2812 | PMID 42636000 Get It

Importance Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development. Observations Transactive response DNA-binding protein 43 kDa (TDP-43) pathology is observed across a range of clinically defined neurodegenerative disorders including limbic predominant age-related encephalopathy (LATE), most cases of amyotrophic lateral sclerosis (ALS), inclusion body myositis, multisystem proteinopathy, and approximately half the cases of frontotemporal dementia (FTD). Despite this shared biology, the current nosology for these neurodegenerative disorders is based on their distinct clinical phenotypes. An alternative approach recognizes the central role of TDP-43 pathology in disease pathogenesis, reserving the use of clinical terms like ALS, FTD, or LATE to describe phenotypic manifestations of underlying pathobiology. This approach also recognizes the converging biomarker and neuropathological data indicating that pathology begins presymptomatically, before the overt clinical manifestations of disease appear. Conclusions and Relevance In proposing a pathobiological definition of disease, the goal is to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.
Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis
Ko, A.K. , Chrysafi, Pavlina , Zon, Rebecca L., Houghton, Damon E. , Ghorbanzadeh, Atefeh , Sastow, Dahniel, Alladi, Sai Swetha, Georgen, Maria, Prabhu, Abishta, Pachpande, Vrushali , Valisekka, Sai Sudha , Jahagirdar, Balkrishna, Peseski, Andrew M. , Gangaraju, Radhika , Zheng, Guoliang , Bhagirath, Vinai Chander, Godoy, Alejandro , Boldrini, Valentina , Betti, Silvia, Rossi, Elena, Berry, Jonathan , Maffioli, Margherita , Nayak, Amiya Ranjan , Dhawan, Rishi, Chiasakul, Thita , Lauw, Mandy N. , Tremblay, Douglas , Ko, Amica Kurniati , Chrysafi, Pavlina , How, Joan , Houghton, Damon E , Ghorbanzadeh, Atefeh , Pachpande, Vrushali , Kapoor, Sargam , Peseski, Andrew , Desai, Ruchi , Dalmia, Shreyash , Godoy, Alejandro Daniel , Iurlo, Alessandra , Cattaneo, Daniele , Vannucchi, Alessandro M , Boldrini, Valentina , De Stefano, Valerio , Ageno, Walter , Berry, Jonathan , Maffioli, Margherita , Aggarwal, Mukul , Chiasakul, Thita , Sanfilippo, Kristen , Hobbs, Gabriela S , Mascarenhas, John , Baumann Kreuziger, Lisa , Patell, Rushad D , Beckman, Joan D , Lauw, Mandy N , Zon, Rebecca L. , Sastow, Dahniel L. , Georgen, Maria R. , Bhagirath, Vinai C. , Guglielmelli, Paola , Vannucchi, Alessandro M. , Stefano, Valerio De , Betti, Silvia, Rossi, Elena, Ageno, Walter , Dhawan, Rishi , Hobbs, Gabriela , Mascarenhas, John , Hoffman, Ronald , Kreuziger, Lisa Baumann , Beckman, Joan D.

Mayo Clinic

Blood Advances | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020925 | PMID 42623680 Get It

Myeloproliferative neoplasm (MPN) patients are at risk of splanchnic vein thromboses (SVT). Prior studies have failed to demonstrate a benefit of hydroxyurea therapy in preventing recurrent thrombosis after SVT, but are limited by small sample sizes and inability to account for starting, stopping, or switching of cytoreductive therapies. To better assess the impact of cytoreductive therapy on thrombosis recurrence, we performed a retrospective cohort study of MPN-SVT patients from the international GASTRO-MPN Consortium, treating cytoreductive therapy as a time-dependent covariate. We identified 757 patients, of which 43% were treated with cytoreductive therapy. During a median follow-up of 7.4 years, 256 patients (34%) had thrombosis recurrence; 145 (19%) had SVT extension/recurrence/TIPS thrombosis, 138 (18%) an thrombosis recurrence outside the splanchnic bed (74% were venous). Additionally, 262 patients (35%) experienced clinically relevant bleeding and 170 (22%) died. After adjusting for age, sex, prior thrombosis, timing of MPN diagnosis relative to SVT, anticoagulation initiation within 30 days of SVT diagnosis, MPN type, JAK2 status, other cancers and cirrhosis, cytoreductive therapy was associated with a decreased risk of recurrent thrombosis (HR 0.67 95%CI 0.50-0.89, p=0.01). This was driven by a lower risk of SVT extension/recurrence (HR 0.62 95%CI 0.42-0.90, p=0.01) but not by extra-splanchnic thrombosis recurrence (HR 0.97 95%CI 0.72-1.30, p=0.82). In a subgroup of patients without erythrocytosis/thrombocytosis at initial SVT (n=275), cytoreductive therapy was associated with a HR 0.65 (95%CI 0.40-1.07, p=0.09) for recurrent thrombosis. These data support the use of cytoreductive therapy in MPN-SVT patients to prevent recurrent thrombosis, particularly SVT extension/recurrence.